Diagnoses and antipsychotic treatment among youths in a public mental health system

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 205-211

  Patel, Nick C ^a   Crismon, M Lynn ^b   Shafer, Alan ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Texas Health and Human Services Commission   (United States)

Author keywords

Adolescents; Antipsychotics; Children

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COMORBIDITY; CONDUCT DISORDER; DEPRESSION; DISEASE ASSOCIATION; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MENTAL HEALTH SERVICE; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHOOL CHILD; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICAID; MENTAL DISORDERS; TEXAS;

EID: 33144487248     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G203     Document Type: Article

References (30)

1. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44:548-56.
2. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004;158:753-9.
3. Pappadopulos E, Jensen PS, Schur SB, et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002;28:111-21.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
5. Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA study. J Am Acad Child Adolesc Psychiatry 1996;35:865-77.
6. Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry 2003;42:132-44.
7. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
8. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62:239-48.
9. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39:509-16.
10. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.
11. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavioral disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-36.
12. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001;11:5-13.
13. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention- deficit hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004;14:11-28.
14. Pappadopulos E, MacIntyre JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive Youth (TRAAY): part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-61.
15. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004;14:243-54.
16. Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA 2004;292:379-81.
17. Hughes CW, Emslie GJ, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1442-54.
18. Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 2004;16:3-13.
19. Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment. Biol Psychiatry 2001;49:1082-90.
20. DelBello M, Grcevich S. Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. J Clin Psychiatry 2004;65(suppl 6):12-9.
21. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-23.
22. DelBello MP, Kowatch R, Stanford KE, et al. Double-blind comparison of divalproex versus quetiapine monotherapy for adolescent mania (abstract). Presented at the 51 st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24,2004.
23. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:213-35.
24. Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):7-19.
25. Patel NC, Crismon ML, Hoagwood K, Jensen PS. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol 2005;15:270-84.
26. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004;350:1489-91.
27. Hunziker ME, DeLeon A, Patel NC, Crismon ML, Shafer A, Bettinger T. Symptom profiles of children and adolescents with a diagnosis of ADHD, bipolar disorder, or depressive disorder. J Child Adolesc Psychopharmacol 2004;14:509-10.
28. Emslie GJ, Hughes CW, Crismon ML, et al. A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004;43:519-27.
29. Quam L, Ellis LBM, Venus P, Clouse J, Taylor CG, Leatherman S. Using claims data for epidemiological research: the concordance of claim-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;31:498-507.
30. Maselli JH, Gonzales R. Measuring antibiotic prescribing practices among ambulatory physicians: accuracy of administrative claims data. J Clin Epidemiol 2001;54:196-201.